RE: Mugged4 Jun 2018 14:23
I feel if so called deramping is bad then so called ramping is same too. There are people on this board posting 50+ times a day saying 200p +, back to 850p etc etc..
I am very interested to know what do they understand about drug approval process and clinical trials?
Look at other companies which have fallen after failed P3 trails or history when people told it was oversold, e.g. Capita, TPOP, CLLN to name the ones I know. They never went to same levels. A good example of Bio with failed P3 trials will be OXB, it never reached to same level (still down 85%) in past decade of where it was before failed trial news..!
I would not even suggest people to average down at this point as this is still ramped up at this price. 38M MCAP is high for a bio company with drug in failed P3 trials, ongoing phase II trial and one drug in preclinical stage. It would take years to recover and massive dilutions during this period.
VAL has 1 drug completed its P2 trials and 2nd about to complete (2 more compaound in preclinical stage) and look at that MCAP to compare.
Ready for this post to be bashed by rampers.. but as I said, how much do you know about drug approval? GLA